Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV

Archives of Internal Medicine

Volumn 157, Issue 17, 1997, Pages 1972-1980

  Pinkerton, Steven D ^a   Holtgrave, David R ^a   Pinkerton, Heidi J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ARTICLE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0030963729     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.17.1972     Document Type: Article

References (63)

1. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med. 1995;322:444-451.
2. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996;45:468-472.
3. Wong ES, Stotka JL, Chinchilli VM, Williams DS, Stuart CG, Markowitz SM. Are universal precautions effective in reducing the number of occupational exposures among health care workers? JAMA. 1991;265:1123-1128.
4. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929-933.
5. Tokars JI, Marcus R, Culver DH, et al, for the CDC Cooperative Needlestick Surveillance Group. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med. 1993;118:913-919.
6. Connor EM, Sperling RS, Gelbert R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331:1173-1180.
7. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties JAMA. 1996;275:1483-1488.
8. Centers for Disease Control. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding post-exposure use. MMWR Morb Mortal Wkly Rep. 1990;39 (No. RR-1):1-14.
9. Henderson DK. Postexposure chemoprophylaxis for occupational exposure to human immunodeficiency virus type 1: current status and prospects for the future. Am J Med. 1991;91(suppl):319S-322S.
10. Puro V, Ippolito G, Guzzanti E, et al, and the Italian Study Group on Occupational Risk of HIV Infection. Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. AIDS. 1992;6:963-969.
11. Schmitz SH, Scheding S, Voliotis D, Rasokat H, Diehl V, Schrappe M. Side-effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Ann Hematol. 1994;69:135-138.
12. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995;171:1166-1171.
13. HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy. Lancet. 1993;341:1077-1078.
14. Durand E, Le Jeunne C, Hugues F-C. Failure of prophylactic zidovudine after suicidal self-inoculation with HIV-infection blood. N Engl J Med. 1991;324:1062.
15. Lange JMA, Boucher CB, Hollak CEM, et al. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med. 1990;322:1375-1377.
16. Looke DFM, Grove DI. Failed prophylactic zidovudine after needlestick injury. Lancet. 1990;335:1280.
17. New drugs for HIV infection. Med Lett Drugs Ther. 1996;38:35-37.
18. Harrigan R. Measuring viral load in the clinical setting. J Acquir Immune Defic Syndr. 1995;10(suppl 1):S34-S40.
19. Staszewski S. Zidovudine and lamivudine: results of phase III studies. J Acquir Immune Defic Syndr. 1995;10(suppl 1):S57.
20. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
21. Richman DD. HIV therapeutics. Science. 1996;272:1886-1888.
22. Holtgrave DR. Cost analysis and HIV prevention programs. Am Psychol. 1994; 49:1088-1089.
23. Holtgrave DR, Qualls NL, Graham JD. Economic evaluation of HIV primary prevention. Ann Rev Public Health. 1996;17:467-488.
24. Gorsky RD, Farnham PG, Straus WL, et al. Preventing perinatal transmission of HIV costs and effectiveness of a recommended intervention. Public Health Rep. 1996;111:335-341.
25. Mansergh G, Haddix AC, Steketee RW, et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA. 1996;276:139-145.
26. Mauskopf JA, Paul JE, Wichman DS, White AD, Tilson HH. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. JAMA. 1996;276:132-138.
27. Laufer FN, Chiarello LA. Application of cost-effectiveness methodology to the consideration of needlestick-prevention technology. Am J Infect Control. 1994;22: 75-82.
28. Haiduven DJ, DeMaio TM, Stevens DA. A five-year study of needlestick injuries: significant reduction associated with communication, education, and convenient placement of sharps containers. Infect Control Hosp Epidemiol. 1992;13:265-271.
29. Skolnick R, LaRocca J, Barba D, Palcius L. Evaluation and implementation of a needleless intravenous system: making needlesticks a needless problem. Am J Infect Control. 1993;21:39-41.
30. Yassi A, McGill ML, Khokhar JB. Efficacy and cost-effectiveness of a needleless intravenous access system. Am J Infect Control. 1995;23:57-94.
31. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press Inc; 1987.
32. Haddix AC, Teutsch SM, Shaffer PA, Duñet DO, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press Inc; 1996.
33. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
34. American Health Consultants. CDC takes aggressive stance on postexposure prophylaxis. AIDS Alert. 1996;11:73-75.
35. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44:1303-1312.
36. Farnham PG, Gorsky RD, Holtgrave DR, Jones WK, Guinan ME. Counseling and testing for HIV prevention: cost, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep. 1996;111:44-53.
37. Guinan ME, Farnham PG, Holtgrave DR. Estimating the value of preventing a human immunodeficiency virus infection. Am J Prevent Med. 1994;10:1-4.
38. Gable CB, Tierce JC, Simison D, Ward D, Motte K. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr. 1996;12:413-420.
39. Hurley SF, Kaldor JM, Gardiner S, Carlin JB, Assuno RM, Evans DB. Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immune Defic Syndr. 1996;12:371-378.
40. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270: 474-478.
41. Pinkerton SD, Holtgrave DR. Lifetime costs of HIV/AIDS medical care. J Acquir Immune Defic Syndr. 1997;14:380-381.
42. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr. In press.
43. Holtgrave DR, Qualls NL. Threshold analysis and HIV prevention programs. Med Decis Making. 1995;15:311-317.
44. McCray E, and the Cooperative Needlestick Surveillance Group. Occupational risk of the acquired immunodeficiency syndrome among health care workers. N Engl J Med. 1986;314:1127-1132.
45. Ganiats TG, Wong AF. Evaluation of cost-effectiveness research: a survey of recent publications. Fam Med. 1991;23:457-462.
46. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J. 1993;148:927-929.
47. Tolley GL, Kenkel D, Fabian R, eds. Valuing Health for Policy: An Economic Approach. Chicago, III: University of Chicago Press; 1994.
48. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health. 1996; 86:1442-1445.
49. Pinkerton SD, Holtgrave DR, Valdiserri RO. Cost-effectiveness of HIV prevention skills training for men who have sex with men. AIDS. 1997;11:347-357.
50. Pinkerton SD, Abramson PR. Evaluating the risks: a Bernoulli process model of HIV infection and risk reduction. Eval Rev. 1993;17:504-528.
51. Allen UD, Read S, Gafni A. Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: an economic analysis. Clin Infect Dis. 1992;14: 822-830.
52. Ramsey SD, Nettleman MD. Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers. Med Decis Making. 1992;12:142-148.
53. Henderson DK, Gerberding JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis. 1989;160:321-327.
54. Hamory BH. Underreporting of needlestick injuries in a university hospital. Am J Infect Control. 1983;11:174-177.
55. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1995:7.
56. Centers for Disease Control and Prevention. Guidelines for prevention of transmission of human immunodeficiency virus hepatitis B virus to health-care and public-safety workers. MMWR Morb Mortal Wkly Rep. 1989;38(S-6):5.
57. Henry K, Campbell S, Jackson B, et al. Long-term follow-up of health care workers with work-site exposure to human immunodeficiency virus. JAMA. 1990; 263:1765.
58. Treloar CJ, Higginbotham N, Malcom JA, Sutherland DC, Berenger S. The personal experience of Australian health-care workers accidentally exposed to risk of HIV infection. AIDS. 1995;9:1385-1386.
59. Beekmann SE, Vlahov D, Koziol DE, McShalley ED, Schmitt JM, Henderson DK. Temporal association between implementation of universal precautions and a sustained, progressive decrease in percutaneous exposures to blood. Clin Infect Dis. 1994;18:562-569.
60. Lawrence VA, Gafni A, Kroenke K. Preoperative HIV testing: is it less expensive than universal precautions? J Clin Epidemiol. 1993;11:1219-1227.
61. Lulloff SJ, Vergeront JM, Druckenmiller J, Hoxie NJ. The incidence of needlestick and sharps injuries and use of safer devices in Wisconsin hospitals. Wis Med J. 1996;95:379-381.
62. Orenstein R, Reynolds L, Karabaic M, Lamb A, Markowitz SM, Wong ES. Do protective devices prevent needlestick injuries among health care workers? Am J Infect Control. 1995;23:344-351.
63. Stock SR, Gafni A, Bloch RF. Universal precautions to prevent HIV transmission to health care workers: an economic analysis. Can Med Assoc J. 1990;142:937-946.